GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rakovina Therapeutics Inc (OTCPK:RKVTF) » Definitions » Investments And Advances

RKVTF (Rakovina Therapeutics) Investments And Advances : $0.00 Mil (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Rakovina Therapeutics Investments And Advances?

Rakovina Therapeutics's Investments And Advances for the quarter that ended in Sep. 2024 was $0.00 Mil.


Rakovina Therapeutics Investments And Advances Historical Data

The historical data trend for Rakovina Therapeutics's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rakovina Therapeutics Investments And Advances Chart

Rakovina Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Investments And Advances
- - -

Rakovina Therapeutics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Rakovina Therapeutics Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Rakovina Therapeutics Business Description

Traded in Other Exchanges
Address
595 Burrard Street, P.O. Box 49314, Suite 2600, Three Bentall Centre, Vancouver, BC, CAN, V6B 0A5
Rakovina Therapeutics Inc is engaged in drug discovery research, preclinical and clinical development, and regulatory affairs necessary to advance breakthrough innovations to become potential life-changing treatments in the oncology field. Its oncology pipeline has the potential to deliver biomarker-driven treatments for patients across multiple tumor types. Some of its products in the pipeline include kt-2000 AI, kt-3000 series. Rakovina gained exclusive use of the Deep Docking AI Platform, enabling it to significantly speed up identifying potential drugs for DNA damage response.